Patents by Inventor Anil Cashikar

Anil Cashikar has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Modulators of alpha-synuclein toxicity
    Patent number: 10526651
    Abstract: Disclosed are compositions and methods for modulating expression of genes that function at the step of ER to Golgi trafficking. Compounds that modulate expression of these genes or activity of the encoded proteins can be used to inhibit alpha-synuclein mediated toxicity and used to treat or prevent synucleinopathies such as Parkinson's disease. Also disclosed are methods of identifying inhibitors of alpha-synuclein mediated toxicity.
    Type: Grant
    Filed: January 18, 2013
    Date of Patent: January 7, 2020
    Assignees: Whitehead Institute for Biomedical Research, The Curators of the University of Missouri
    Inventors: Susan L. Lindquist, Aaron D. Gitler, Anil Cashikar, Antony A. Cooper, Cole M. Haynes
  • Modulators of alpha-synuclein toxicity
    Patent number: 9879257
    Abstract: Disclosed are genes that, when overexpressed in cells expressing alpha-synuclein, either suppress or enhance alpha-synuclein mediated cellular toxicity. Compounds that modulate expression of these genes or activity of the encoded proteins can be used to inhibit alpha-synuclein mediated toxicity and used to treat or prevent synucleinopathies such as Parkinson's disease. Also disclosed are methods of identifying inhibitors of alpha-synuclein mediated toxicity.
    Type: Grant
    Filed: March 24, 2015
    Date of Patent: January 30, 2018
    Assignee: Whitehead Institute for Biomedical Research
    Inventors: Susan L. Lindquist, Aaron D. Gitler, Anil Cashikar
  • MODULATORS OF ALPHA-SYNUCLEIN TOXICITY
    Publication number: 20160046933
    Abstract: Disclosed are genes that, when overexpressed in cells expressing alpha-synuclein, either suppress or enhance alpha-synuclein mediated cellular toxicity. Compounds that modulate expression of these genes or activity of the encoded proteins can be used to inhibit alpha-synuclein mediated toxicity and used to treat or prevent synucleinopathies such as Parkinson's disease. Also disclosed are methods of identifying inhibitors of alpha-synuclein mediated toxicity.
    Type: Application
    Filed: March 24, 2015
    Publication date: February 18, 2016
    Inventors: Susan L. Lindquist, Aaron D. Gitler, Anil Cashikar
  • Modulators of alpha-synuclein toxicity
    Patent number: 9018003
    Abstract: Disclosed are genes that, when overexpressed in cells expressing alpha-synuclein, either suppress or enhance alpha-synuclein mediated cellular toxicity. Compounds that modulate expression of these genes or activity of the encoded proteins can be used to inhibit alpha-synuclein mediated toxicity and used to treat or prevent synucleinopathies such as Parkinson's disease. Also disclosed are methods of identifying inhibitors of alpha-synuclein mediated toxicity.
    Type: Grant
    Filed: May 12, 2006
    Date of Patent: April 28, 2015
    Assignee: Whitehead Institute for Biomedical Research
    Inventors: Susan L. Lindquist, Aaron D. Gitler, Anil Cashikar
  • Modulators of alpha-synuclein toxicity
    Patent number: 8399241
    Abstract: Disclosed are compositions and methods for modulating expression of genes that function at the step of ER of Golgi trafficking. Compounds that modulate expression of these genes of activity of the encoded proteins can be used to inhibit alpha-synuclein mediated toxicity and used to threat of prevent synucleinopathies such as Parkinson's disease. Also disclosed are methods of identifying inhibitors of alpha-synuclein mediated toxicity.
    Type: Grant
    Filed: December 1, 2005
    Date of Patent: March 19, 2013
    Assignees: Whitehead Institute for Biomedical Research, The Curators of the University of Missouri
    Inventors: Susan L. Lindquist, Aaron D. Gitler, Anil Cashikar, Antony A. Cooper, Cole M. Haynes
  • MODULATORS OF ALPHA-SYNUCLEIN TOXICITY
    Publication number: 20090304664
    Abstract: Disclosed are genes that, when overexpressed in cells expressing alpha-synuclein, either suppress or enhance alpha-synuclein mediated cellular toxicity. Compounds that modulate expression of these genes or activity of the encoded proteins can be used to inhibit alpha-synuclein mediated toxicity and used to treat or prevent synucleinopathies such as Parkinson's disease. Also disclosed are methods of identifying inhibitors of alpha-synuclein mediated toxicity.
    Type: Application
    Filed: May 12, 2006
    Publication date: December 10, 2009
    Applicant: WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH
    Inventors: Susan L. Lindquist, Aaron D. Gitler, Anil Cashikar
  • MODULATORS OF ALPHA-SYNUCLEIN TOXICITY
    Publication number: 20090099069
    Abstract: Disclosed are compositions and methods for modulating expression of genes that function at the step of ER of Golgi trafficking. Compounds that modulate expression of these genes of activity of the encoded proteins can be used to inhibit alpha-synuclein mediated toxicity and used to threat of prevent synucleinopathies such as Parkinson's disease. Also disclosed are methods of identifying inhibitors of alpha-synuclein mediated toxicity.
    Type: Application
    Filed: December 1, 2005
    Publication date: April 16, 2009
    Applicants: WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH, THE CURATORS OF THE UNIVERSITY MISSOURI
    Inventors: Susan L. Lindquist, Aaron D. Gitler, Anil Cashikar, Antony A. Cooper, Cole M. Haynes